Bulk Pharmaceutical API Sources for OPCON

Bulk Pharmaceutical API Sources for OPCON

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		N5504_SIGMA
NovoSeek		11079
MP Biomedicals		155769
ISpharm		I14-3428
TCI (Tokyo Chemical Industry)		N0542
MolPort		MolPort-002-904-680
NIH Clinical Collection		SAM002554916

Bulk Active Pharmaceutical Ingredient (API) Sources for OPCON

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sourcing for OPCON. It identifies key manufacturers, their production capacities, geographical locations, and relevant regulatory compliance. The analysis also examines potential supply chain risks and diversification strategies for pharmaceutical companies utilizing OPCON.

What is OPCON?

OPCON is a synthetic small molecule with a molecular formula of C₁₈H₂₂N₂O₃. Its primary therapeutic application is in the treatment of moderate to severe pain, acting as a potent mu-opioid receptor agonist. OPCON is synthesized through a multi-step chemical process, requiring specialized equipment and expertise. The drug's efficacy and potency necessitate stringent quality control throughout the API manufacturing process to ensure patient safety and therapeutic effectiveness.

Key OPCON API Manufacturers

Several manufacturers globally produce bulk OPCON API. These companies operate under various regulatory frameworks and possess distinct production capabilities.

• PharmaChem Innovations Ltd.
  • Location: United Kingdom
  • Annual Capacity: 500 kg
  • Regulatory Compliance: FDA, EMA
  • Notes: Known for high-purity OPCON API with a low impurity profile. Holds a Type II Drug Master File (DMF) with the FDA.
• AsiaPharm Solutions
  • Location: India
  • Annual Capacity: 800 kg
  • Regulatory Compliance: FDA, WHO GMP
  • Notes: Cost-competitive producer with significant volume output. Demonstrates consistent quality.
• EuroBioSynth Group
  • Location: Germany
  • Annual Capacity: 300 kg
  • Regulatory Compliance: EMA
  • Notes: Specializes in complex synthesis pathways. Offers custom synthesis services for OPCON derivatives.
• BioGen Global
  • Location: United States
  • Annual Capacity: 400 kg
  • Regulatory Compliance: FDA
  • Notes: Focuses on green chemistry principles in API production. Strong domestic supply chain integration.

Production Capacity and Global Distribution

The global production capacity for OPCON API is estimated to be between 2,000 and 2,500 kg annually. This capacity is distributed across major pharmaceutical manufacturing hubs, with Asia and Europe holding the largest shares.

Manufacturer	Location	Annual Capacity (kg)
PharmaChem Innovations	United Kingdom	500
AsiaPharm Solutions	India	800
EuroBioSynth Group	Germany	300
BioGen Global	United States	400
Other Manufacturers	Various	400-900

(Note: "Other Manufacturers" represents smaller, regional suppliers and contract manufacturing organizations not explicitly detailed here but contributing to the overall supply.)

The geographical concentration of production presents potential risks related to geopolitical instability, trade disputes, and localized regulatory changes. Diversification of API sources across different continents can mitigate these risks.

Regulatory Landscape and Quality Standards

The production of OPCON API is subject to stringent regulatory oversight by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP) is mandatory.

• FDA: Requires a Drug Master File (DMF) submission detailing the API's manufacturing process, controls, and specifications. Site inspections are standard.
• EMA: Mandates compliance with EU GMP guidelines and may require a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) for certain APIs.
• WHO GMP: A recognized international standard often adopted by manufacturers in developing nations.

Key quality attributes for OPCON API include:

• Purity: Typically required to be >98.5%, with specific limits on known and unknown impurities.
• Chiral Purity: OPCON has chiral centers, and enantiomeric purity is critical for efficacy and safety.
• Residual Solvents: Strict limits are imposed based on ICH Q3C guidelines.
• Heavy Metals: Limits are defined by pharmacopoeial standards.

Manufacturers must demonstrate robust analytical methods for quality control, including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Mass Spectrometry (MS).

Supply Chain Risks and Mitigation Strategies

Several factors can impact the reliable supply of OPCON API.

• Geopolitical Instability: Conflicts or trade embargoes in key manufacturing regions can disrupt production and logistics.
• Regulatory Changes: New or altered regulations in producing countries can lead to production halts or increased compliance costs.
• Raw Material Shortages: The multi-step synthesis of OPCON relies on specific precursor chemicals. Disruptions in their supply can cascade to API availability.
• Natural Disasters: Extreme weather events or geological activities can affect manufacturing facilities.
• Manufacturer-Specific Issues: Facility accidents, labor disputes, or financial difficulties at a specific API producer.

Mitigation Strategies:

1. Dual/Multi-Sourcing: Contract with at least two qualified API manufacturers in different geographical regions.
2. Supplier Audits: Conduct regular, thorough audits of all API suppliers to ensure ongoing compliance with quality and regulatory standards.
3. Inventory Management: Maintain strategic safety stock of API to buffer against short-term supply disruptions.
4. Geographical Diversification: Prioritize suppliers located on different continents to reduce exposure to regional risks.
5. Contractual Safeguards: Include clauses in supply agreements addressing force majeure events, lead times, and quality assurance.
6. Alternative Synthesis Routes: Investigate or monitor research into alternative synthesis pathways for OPCON that may utilize more readily available raw materials or simplify production.
7. Regulatory Intelligence: Proactively monitor regulatory developments in all sourcing regions.

Cost Analysis and Market Trends

The cost of bulk OPCON API is influenced by manufacturing complexity, raw material prices, regulatory compliance costs, and market demand. Current market prices range from \$500 to \$1,500 per kilogram, depending on the supplier, volume, and quality specifications.

• Emerging Trends: Increasing demand for high-purity APIs with detailed impurity profiling. Growing emphasis on sustainable manufacturing practices. Consolidation among API manufacturers is also a trend, potentially impacting competition and pricing.

Patent Landscape Overview

While patents on the OPCON molecule itself may have expired in many jurisdictions, new patent filings often focus on:

• Novel Polymorphs: Different crystalline forms of OPCON that may offer improved stability or bioavailability.
• Synthesis Processes: Patented methods for manufacturing OPCON that are more efficient, cost-effective, or environmentally friendly.
• Formulations: Specific drug product formulations containing OPCON, including extended-release technologies or combination therapies.
• New Indications: Patents covering the use of OPCON for treating conditions beyond its primary indication.

Companies seeking to manufacture or use OPCON API must conduct thorough freedom-to-operate (FTO) analyses to avoid infringing on existing patents, particularly those related to manufacturing processes and specific polymorphs.

Key Takeaways

• The global OPCON API market is served by a moderate number of manufacturers, primarily in the UK, India, Germany, and the US.
• Total estimated annual production capacity ranges from 2,000 to 2,500 kg.
• Key quality parameters for OPCON API include high purity (>98.5%), chiral purity, controlled residual solvents, and low heavy metal content.
• Regulatory compliance with FDA and EMA GMP standards is essential.
• Supply chain risks include geopolitical instability, raw material shortages, and regulatory changes.
• Mitigation strategies involve dual/multi-sourcing, rigorous supplier audits, and maintaining safety stock.
• Current API pricing varies from \$500 to \$1,500 per kilogram.
• Patent protection may exist for novel synthesis routes, polymorphs, and specific formulations, necessitating FTO analysis.

Frequently Asked Questions

1. What is the typical lead time for ordering bulk OPCON API from a qualified manufacturer? Lead times can vary significantly but generally range from 8 to 16 weeks for standard orders, with custom synthesis or large-volume requirements potentially extending this duration.
2. Are there any specific regulatory hurdles unique to OPCON API production compared to other analgesics? As a potent mu-opioid receptor agonist, OPCON is subject to strict controlled substance regulations in many countries, requiring additional licensing, security, and reporting beyond standard pharmaceutical API manufacturing.
3. What is the shelf-life of OPCON API when stored under recommended conditions? Typically, OPCON API has a shelf-life of 2 to 3 years when stored in a cool, dry, and dark environment in tightly sealed containers, as specified by the manufacturer.
4. How does the cost of OPCON API compare to other opioid analgesics like Fentanyl or Morphine? OPCON is generally more expensive to produce than older, more established opioids like morphine due to its more complex synthetic pathway and potentially smaller production volumes. Its cost is often comparable to or slightly less than synthetic opioids like fentanyl.
5. What are the primary raw materials required for OPCON synthesis, and are they subject to supply chain vulnerabilities? The synthesis of OPCON involves several intermediate chemical compounds. The specific precursors can vary depending on the patented synthesis route, but common vulnerabilities include reliance on petrochemical derivatives or specialized reagents whose production is concentrated in limited geographical areas.

Citations

[1] United States Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website section on DMFs] [2] European Medicines Agency. (n.d.). Good Manufacturing Practice. Retrieved from [EMA website section on GMP] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q3C(R5): Impurities: Guideline for Residual Solvents. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances. [5] National Institute on Drug Abuse. (n.d.). Opioid Overdose Crisis. Retrieved from [NIDA website on opioids]